Concepedia

Julie Macoin

JM

7

Publications

159

Citations

7

H-Index

2014

Active since

Affiliations

Ichnos Sciences (United States)(Current)

Glenmark Pharmaceuticals (Switzerland)

University of Oxford

Nantes Université

Glenmark Pharmaceuticals (India)

Julie Macoin is an author at Ichnos Sciences (United States) specializing in medicine, immunology, and cell biology.

Top concepts

Publications per year

2014–2024

7

Publications

7

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

Barbara Rewerska, Lawrence Sher, Sady Alpizar et al. · Journal of Allergy and Clinical Immunology Global · 2023 · 39 citations · Full text

, , +9

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies

Caroline Breton, Aimable Nahimana, Dominique Aubry et al. · Journal of Hematology & Oncology · 2014 · 32 citations · Full text

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Laura Carretero-Iglesia, O. Hall, Jérémy Berret et al. · Nature Cancer · 2024 · 28 citations · Full text

, , +8

Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma

Blandine Pouleau, Carole Estoppey, Perrine Suere et al. · Blood · 2023 · 19 citations · Full text

ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.

Marie‐Agnès Doucey, Blandine Pouleau, Carole Estoppey et al. · Journal of Clinical Oncology · 2021 · 17 citations

, , +20

Rows per page

1–5 of 7